ACLS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ovejera, A.
Right arrow Articles by Barker, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ovejera, A.
Right arrow Articles by Barker, A.
Annals of Clinical and Laboratory Science, Vol 8, Issue 1, 50-56
Copyright © 1978 by Association of Clinical Scientists

Articles

Chemotherapy of human tumor xenografts in genetically athymic mice

AA Ovejera, DP Houchens, and AD Barker

A series of studies were undertaken to evaluate the chemotherapeutic response to various antineoplastic drugs of human breast (MX-1) or colon (CX-2) tumor xenografts growing in genetically athymic (nude) mice. Fragments (2mm3) of either tumor type were implanted subcutaneously into the subaxillary region of NIH Swiss nude mice, and single drug therapy was started when tumors became palpable and were growing progressively. 5-Fluorouracil (5-FU) administered on a Q7DX3 schedule starting on Day 21 post tumor implantation elicited significant retardation in the growth rate of CX-2 tumor. A single treatment with methyl-CCNU induced temporary tumor regression. Against MX-1 tumor, both cyclophosphamide and melphalan induced tumor regressions with no recurrence. 5-FU slowed but did not arrest growth of MX-1 tumor. These tumor systems grown in nude mice appear to be suitable models for in vivo screening of anticancer agents that would prove clinically active.


This article has been cited by other articles:


Home page
 Ann. Surg. Oncol.Home page
Y. Sakurai, I. Yoshida, S. Kamoshida, K. Inaba, J. Isogaki, Y. Komori, I. Uyama, and Y. Tsutsumi
Effects of Combined Administration of DPD-Inhibitory Oral Fluoropyrimidine, S-1, Plus Paclitaxel on Gene Expressions of Fluoropyrimidine Metabolism-Related Enzymes in Human Gastric Xenografts
Ann. Surg. Oncol., August 1, 2008; 15(8): 2301 - 2309.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
S. Kumar, H. Kishimoto, H. L. Chua, S. Badve, K. D. Miller, R. M. Bigsby, and H. Nakshatri
Interleukin-1{alpha} Promotes Tumor Growth and Cachexia in MCF-7 Xenograft Model of Breast Cancer
Am. J. Pathol., December 1, 2003; 163(6): 2531 - 2541.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. Ido, H. Uto, A. Moriuchi, K. Nagata, Y. Onaga, M. Onaga, T. Hori, S. Hirono, K. Hayashi, T. Tamaoki, et al.
Gene Therapy Targeting for Hepatocellular Carcinoma: Selective and Enhanced Suicide Gene Expression Regulated by a Hypoxia-inducible Enhancer Linked to a Human {{alpha}}-Fetoprotein Promoter
Cancer Res., April 1, 2001; 61(7): 3016 - 3021.
[Abstract] [Full Text]

Home page
 Clin. Cancer Res.Home page
K. Fujimoto-Ouchi, Y. Tanaka, and T. Tominaga
Schedule Dependency of Antitumor Activity in Combination Therapy with Capecitabine/5'-Deoxy-5-fluorouridine and Docetaxel in Breast Cancer Models
Clin. Cancer Res., April 1, 2001; 7(4): 1079 - 1086.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1978 by the Association of Clinical Scientists.